Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-263589
Filing Date
2025-11-04
Accepted
2025-11-04 07:30:47
Documents
52
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q kura-20250930.htm   iXBRL 10-Q 2467636
2 EX-10.2 kura-ex10_2.htm EX-10.2 57036
3 EX-31.1 kura-ex31_1.htm EX-31.1 12239
4 EX-32.1 kura-ex32_1.htm EX-32.1 10349
  Complete submission text file 0001193125-25-263589.txt   8087701

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kura-20250930.xsd EX-101.SCH 940858
55 EXTRACTED XBRL INSTANCE DOCUMENT kura-20250930_htm.xml XML 1341312
Mailing Address 4930 DIRECTORS PLACE, SUITE 500 SAN DIEGO CA 92121
Business Address 4930 DIRECTORS PLACE, SUITE 500 SAN DIEGO CA 92121 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37620 | Film No.: 251446458
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)